Latest Insider Transactions at Alaunos Therapeutics, Inc. (TCRT)
This section provides a real-time view of insider transactions for Alaunos Therapeutics, Inc. (TCRT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Alaunos Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Alaunos Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 01
2023
|
Kevin S. Boyle Sr. Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
68,014
-7.85%
|
$0
$0.14 P/Share
|
|
Nov 29
2022
|
Jaime Vieser |
BUY
Open market or private purchase
|
Indirect |
1,250,000
+50.0%
|
$0
$0.65 P/Share
|
|
Nov 29
2022
|
Robert W Postma |
BUY
Open market or private purchase
|
Indirect |
750,000
+13.04%
|
$0
$0.65 P/Share
|
|
Aug 30
2022
|
Kevin S. Boyle Sr. Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
18,750
-2.12%
|
$37,500
$2.41 P/Share
|
|
Jun 22
2022
|
Holger Weis |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+19.98%
|
-
|
|
Jun 22
2022
|
Christopher Bowden Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+47.52%
|
-
|
|
Jun 22
2022
|
Jaime Vieser |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+5.09%
|
-
|
|
Jun 22
2022
|
Robert W Postma |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+3.12%
|
-
|
|
Jun 22
2022
|
James Huang Director |
BUY
Grant, award, or other acquisition
|
Direct |
160,000
+29.81%
|
-
|
|
Jun 22
2022
|
Mary Thistle Director |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+47.06%
|
-
|
|
Dec 22
2021
|
Eleanor De Groot EVP, Operations |
SELL
Open market or private sale
|
Direct |
20,132
-7.83%
|
$20,132
$1.27 P/Share
|
|
Nov 17
2021
|
Kevin S. Boyle Sr. Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
9,116
+1.02%
|
$9,116
$1.4 P/Share
|
|
Nov 16
2021
|
Kevin S. Boyle Sr. Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
884
+0.1%
|
$884
$1.4 P/Share
|
|
Sep 29
2021
|
Jaime Vieser |
BUY
Open market or private purchase
|
Direct |
100,000
+12.42%
|
$100,000
$1.91 P/Share
|
|
Sep 02
2021
|
Robert W Postma |
BUY
Open market or private purchase
|
Indirect |
54,492
+1.27%
|
$54,492
$1.73 P/Share
|
|
Sep 02
2021
|
Robert W Postma |
BUY
Open market or private purchase
|
Direct |
20,508
+1.68%
|
$20,508
$1.73 P/Share
|
|
Sep 02
2021
|
Heidi Hagen Director |
BUY
Open market or private purchase
|
Direct |
23,770
+14.01%
|
$23,770
$1.76 P/Share
|
|
Sep 01
2021
|
James Huang Director |
BUY
Open market or private purchase
|
Direct |
100,000
+48.0%
|
$100,000
$1.71 P/Share
|
|
Sep 01
2021
|
Holger Weis |
BUY
Open market or private purchase
|
Direct |
50,000
+29.38%
|
$50,000
$1.83 P/Share
|
|
Aug 30
2021
|
Kevin S. Boyle Sr. Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
875,000
+50.0%
|
-
|
|
May 17
2021
|
Raffaele Baffa Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
80,645
+22.32%
|
-
|
|
Mar 04
2021
|
Christopher Bowden Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,167
+50.0%
|
-
|
|
Mar 04
2021
|
J Kevin Buchi Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,167
+50.0%
|
-
|
|
Mar 04
2021
|
James Huang Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,333
+50.0%
|
-
|
|
Mar 04
2021
|
Robert W Postma |
BUY
Grant, award, or other acquisition
|
Direct |
2,500
+0.21%
|
-
|
|
Mar 04
2021
|
Mary Thistle Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+50.0%
|
-
|
|
Mar 04
2021
|
Jaime Vieser |
BUY
Grant, award, or other acquisition
|
Direct |
4,167
+0.68%
|
-
|
|
Mar 04
2021
|
Holger Weis |
BUY
Grant, award, or other acquisition
|
Direct |
4,167
+5.61%
|
-
|
|
Mar 04
2021
|
Eleanor De Groot EVP, Operations |
BUY
Grant, award, or other acquisition
|
Direct |
50,825
+16.5%
|
-
|
|
Mar 04
2021
|
Heidi Hagen Director |
BUY
Grant, award, or other acquisition
|
Direct |
90,000
+42.43%
|
-
|
|
Mar 04
2021
|
Robert Hadfield Chief Legal Officer and Sec. |
BUY
Grant, award, or other acquisition
|
Direct |
43,500
+19.74%
|
-
|
|
Mar 04
2021
|
Jill Buck EVP, GM Gene Therapy |
BUY
Grant, award, or other acquisition
|
Direct |
31,500
+12.0%
|
-
|
|
Jan 08
2021
|
Robert Hadfield Chief Legal Officer and Sec. |
SELL
Open market or private sale
|
Direct |
26,500
-16.58%
|
$79,500
$3.12 P/Share
|
|
Jan 08
2021
|
Kevin G Lafond SVP, Treasurer & CAO |
SELL
Open market or private sale
|
Direct |
18,020
-21.98%
|
$54,060
$3.09 P/Share
|
|
Jan 08
2021
|
Jill Buck EVP, GM Gene Therapy |
SELL
Open market or private sale
|
Direct |
27,894
-12.27%
|
$83,682
$3.12 P/Share
|
|
Jan 04
2021
|
Laurence James Neil Cooper President and CEO |
SELL
Open market or private sale
|
Direct |
105,693
-5.55%
|
$211,386
$2.71 P/Share
|
|
Jan 04
2021
|
Eleanor De Groot EVP, Operations |
SELL
Open market or private sale
|
Direct |
21,620
-9.48%
|
$43,240
$2.72 P/Share
|